Mining Stocks; NORTH ARROW OPTIONS HOPE BAY ORO GOLD PROJECT TO CHELSEA MINERALS INC.
February 3, 2011 (Investorideas.com Mining stocks newswire) North Arrow Minerals Inc. (NAR: TSXV) is pleased to announce an option agreement with Chelsea Minerals Inc., (NEX:CCC.H) allowing Chelsea the right to earn a 60% interest in North Arrow's Hope Bay Oro gold project in Nunavut. The Oro project consists of five leases covering an area of over 10,000 acres that adjoins the new Hope Bay Gold Mine. Under the terms of the agreement, Chelsea may earn up to a 60% interest in the project by making an initial cash payment of $50,000 and spending $5 million over a five year period. A minimum expenditure of $500,000 is required in the first year.
In conjunction with entering into the Option Agreement, Chelsea has entered into a Letter of Intent with Sennen Resources Ltd ("Sennen") (TSXV: SN), which contemplates that Sennen will acquire all of the issued and outstanding shares of Chelsea by way of a share exchange, whereby, pursuant to a Plan of Arrangement, shareholders of Chelsea would receive one share of Sennen for every two and one half common shares of Chelsea held by them. Sennen has over $15 million in its treasury and can fund the exploration obligations for the Hope Bay project without the need to raise any further capital.
North Arrow's Oro project directly adjoins the Doris North mine being brought into production by Hope Bay Mining Ltd (a wholly owned subsidiary of Newmont Mining Corporation). Hope Bay Mining's project includes the Doris, Boston and Madrid deposits that contain an estimated 9 million ounces of gold and collectively represent one of the largest undeveloped gold deposits in Canada. The deposits are located within an 80 km long Archean greenstone belt, the northern 10 km of which is covered by North Arrow's mining leases. Hope Bay Mining is continuing aggressive exploration in parallel with mine development which confirms their expectations of making further discoveries.
The Oro project hosts numerous gold showings and potentially gold bearing structures which have been evaluated by only minimal exploration. Several high grade native silver deposits, mined in the 1970's, are also located on the property and the potential exists to find larger hidden silver deposits associated with structures since identified across the property.
Exploration work on the Oro project will be focused on two mineralized zones; the Ida Point prospect at the northern end of the property and the Wombat zone at the southern end. Exploration at Ida Point will be centred on the 600 m long Elu shear zone, where surface trenching over a 400 m strike length has returned significant gold values including 11.6 grams per tonne gold (g/t Au) over 1.9 m and 24.7 g/t Au over 5 m. A four hole diamond drill program in 1998 returned downhole intersections of 14.3 g/t Au over 2 m and 5.5 g/t Au over 6 m. Wombat is a gold bearing shear zone which has been traced for more than 1,000 m near the property's southern boundary. A number of short holes were previously drilled at Wombat with one returning 40.3 g/t Au over 2.7 m.
The location of the Oro project, situated along strike from Hope Bay Mining's multi-million ounce gold deposits, represents a significant opportunity for North Arrow and will supplement the Company's diamond exploration activities in northern Canada. The exploration program for the Oro project will be managed by North Arrow and the permitting process is underway with plans to commence drilling and surface exploration as early as possible in 2011. Access to the property is enhanced by its proximity to Hope Bay Mining's Roberts Bay port facility and airstrip, located two kilometres and three kilometres to the southwest, respectively.
Completion of the Option Agreement with Chelsea and its Plan of Arrangement with Sennen remains subject to completion of a satisfactory due diligence review and receipt of all necessary regulatory and shareholder approvals, including but not limited to acceptance of the transaction by the NEX and, if required, the TSX Venture Exchange.
North Arrow's exploration programs are conducted under the supervision of Gordon Clarke, P.Geol (NT&NU), Vice President, Exploration for North Arrow and a qualified person under NI 43-101.
North Arrow Minerals Inc.
/s/ "D. Grenville Thomas"
D. Grenville Thomas
President and CEO
For further information, please contact:
D. Grenville Thomas
President and CEO
Tel: 604-668-8355
Gordon Clarke
Vice President, Exploration
Tel: 867-873-8483
The TSX Venture Exchange has not reviewed, and does not accept responsibility for the adequacy of this release.
Thursday, February 03, 2011
Biotech/Pharma Profile Update for BioSante Pharmaceuticals, Inc.
Key Highlight: BioSante Pharmaceuticals is Only Company in World In Phase III Clinical Development for Treatment of Female Sexual Dysfunction
Point Roberts, WA, LINCOLNSHIRE, Ill - February 3, 2011 Investorideas.com, a leader in sector research, updates the company profile for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for investors following biotech and pharma stocks.
Recent News:
"BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Provide Update on LibiGel Safety Study at International Society for the Study of Women's Sexual Health Meeting"
LINCOLNSHIRE, Ill. - February 3, 2011 BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced that it will provide a LibiGel safety study update, and is supporting two clinical symposia at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH) being held from February 10-13, 2011 at the Doubletree Paradise Valley resort in Scottsdale, Arizona. More than 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting.
Read the full news release, click here .
Company Overview:
BioSante (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. www.biosantepharma.com
The BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Read the full BPAX Investor Presentation at: http://www.investorideas.com/CO/BPAX/news/2011/BPAX-Presentation-012111.pdf
Financial Highlights
Full LibiGel Brochure at: http://www.investorideas.com/CO/BPAX/news/2011/LibiGel-Brochure-Jan2011.pdf
LibiGel®* Treatment of Women with
Hypoactive Sexual Desire Disorder (HSDD)
LibiGel® is a gel formulation of testosterone in development that is quickly absorbed through the skin after a once-daily application of a pea-sized dose of gel on the upper arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and painless manner. Though generally characterized as a male hormone, testosterone also is present in women and its deficiency has been found to decrease libido or sex drive. In addition, studies have shown that testosterone therapy can increase bone density, raise energy levels and improve mood, in addition to boosting sexual desire and activity.
Regulatory Status
The LibiGel clinical development program, in consultation and agreement with the FDA, has been designed to show that LibiGel can safely improve women's sexual desire and the frequency of satisfying sexual events and decrease personal distress associated with low sexual desire in women with HSDD. BioSante is conducting three Phase III LibiGel clinical studies and BioSante's objective is to submit a new drug application (NDA) to the FDA in 2011 for a potential approval in 2012.
Progress and Plans in Phase III:
Currently, BioSante is conducting three Phase III clinical studies to demonstrate the safety and efficacy of LibiGel to increase sexual desire and satisfying sexual events and to decrease distress associated with the decreased desire. Two Phase III safety and efficacy trials that are underway are randomized, double blind, placebo-controlled trials which will enroll approximately 500 surgically menopausal women each for six-months of treatment. BioSante is conducting these trials under an FDA agreed special protocol assessment (SPA). In addition, BioSante has another SPA agreement with the FDA related to treatment of naturally menopausal women. The SPA process and agreement confirms the FDA's position that FSD and HSDD are true conditions that women experience, with measurable endpoints, that can be evaluated and which deserve therapeutic options. It also affirms that the FDA agrees that the LibiGel Phase III safety and efficacy clinical trial design, clinical endpoints, sample size, planned conduct and statistical analyses are acceptable to support regulatory approval. Further, it provides assurance that these agreed measures will serve as the basis for regulatory review and the decision by the FDA to approve an NDA for LibiGel.
In addition to the two Phase III safety and efficacy trials covered by the SPA, BioSante is conducting one Phase III cardiovascular and breast cancer safety study of LibiGel, which also is underway. The safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular events and breast cancer study of between 2,750 and
4,000 women exposed to LibiGel or placebo. BioSante will follow the women enrolled in the safety study for a total of 5 years. However, after an average of 12 months' exposure BioSante intends to submit a LibiGel NDA for review and potential approval by FDA.
The LibiGel safety study is tracking a composite of cardiovascular events including cardiovascular death, myocardial infarction and stroke in women with FSD who are 50 years of age or older and have at least two cardiovascular risk factors such as hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of cardiovascular events. The incidence of breast cancer also will be tracked throughout the study.
BioSante has reported that in the first 2,750 women enrolled comprising approximately 2,700 women-years of exposure, there have been only 14 adjudicated cardiovascular events even though the safety study is enrolling women with a higher risk of cardiovascular events. To date, over 2,750 women have been enrolled.
BioSante's obective is to submit the LibiGel NDA in 2011 for a potential FDA approval in 2012.
Contact BioSante Pharmaceuticals
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220; azachary@mckinneychicago.com
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
To the extent any statements made in this news release deal with information that is not hist orical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Disclaimer: This news release is part of a monthly information distribution program for BioSante (BPAX) (one thousand dollars per month). Investorideas.com is a third party publisher of news and research .All information on featured companies is prepared by the company or taken from public filings and news releases. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
About InvestorIdeas.com :
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech/pharma, mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Visit our Biotech investor portal : www.biotechindustrystocks.com
Research more biotech stocks at the Biotech stocks Directory
Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante Pharmaceuticals Inc.
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411: cvanzant@investorideas.com
Key Highlight: BioSante Pharmaceuticals is Only Company in World In Phase III Clinical Development for Treatment of Female Sexual Dysfunction
Point Roberts, WA, LINCOLNSHIRE, Ill - February 3, 2011 Investorideas.com, a leader in sector research, updates the company profile for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for investors following biotech and pharma stocks.
Recent News:
"BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Provide Update on LibiGel Safety Study at International Society for the Study of Women's Sexual Health Meeting"
LINCOLNSHIRE, Ill. - February 3, 2011 BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced that it will provide a LibiGel safety study update, and is supporting two clinical symposia at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH) being held from February 10-13, 2011 at the Doubletree Paradise Valley resort in Scottsdale, Arizona. More than 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting.
Read the full news release, click here .
Company Overview:
BioSante (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. www.biosantepharma.com
The BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Read the full BPAX Investor Presentation at: http://www.investorideas.com/CO/BPAX/news/2011/BPAX-Presentation-012111.pdf
Financial Highlights
- At December 31, 2010, BioSante had approximately $39M in cash
- Monthly burn rate of approximately $3.5M - $4.0M
- NASDAQ: BPAX
- Recent Price (2/2/11): $1.93
- Market Cap: $150M
- Average Daily Volume: 1.1M
- Common Shares Outstanding: 81.4M
- 52-Week Range: $1.29-$2.50
- Fiscal Year Ends: December 31
- Financial resources to continue corporate strategy
- Late stage pharmaceutical product portfolio with significant growth potential
- LibiGel in three ongoing Phase III safety and efficacy clinical studies
- Elestrin is FDA approved and marketed in the U.S.
- Proprietary cancer vaccines in Phase II clinical trials
- Focused growth strategy
- Management's proven ability to gain FDA approval, implement plans and increase stockholder value
Full LibiGel Brochure at: http://www.investorideas.com/CO/BPAX/news/2011/LibiGel-Brochure-Jan2011.pdf
LibiGel®* Treatment of Women with
Hypoactive Sexual Desire Disorder (HSDD)
LibiGel® is a gel formulation of testosterone in development that is quickly absorbed through the skin after a once-daily application of a pea-sized dose of gel on the upper arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and painless manner. Though generally characterized as a male hormone, testosterone also is present in women and its deficiency has been found to decrease libido or sex drive. In addition, studies have shown that testosterone therapy can increase bone density, raise energy levels and improve mood, in addition to boosting sexual desire and activity.
Regulatory Status
The LibiGel clinical development program, in consultation and agreement with the FDA, has been designed to show that LibiGel can safely improve women's sexual desire and the frequency of satisfying sexual events and decrease personal distress associated with low sexual desire in women with HSDD. BioSante is conducting three Phase III LibiGel clinical studies and BioSante's objective is to submit a new drug application (NDA) to the FDA in 2011 for a potential approval in 2012.
Progress and Plans in Phase III:
Currently, BioSante is conducting three Phase III clinical studies to demonstrate the safety and efficacy of LibiGel to increase sexual desire and satisfying sexual events and to decrease distress associated with the decreased desire. Two Phase III safety and efficacy trials that are underway are randomized, double blind, placebo-controlled trials which will enroll approximately 500 surgically menopausal women each for six-months of treatment. BioSante is conducting these trials under an FDA agreed special protocol assessment (SPA). In addition, BioSante has another SPA agreement with the FDA related to treatment of naturally menopausal women. The SPA process and agreement confirms the FDA's position that FSD and HSDD are true conditions that women experience, with measurable endpoints, that can be evaluated and which deserve therapeutic options. It also affirms that the FDA agrees that the LibiGel Phase III safety and efficacy clinical trial design, clinical endpoints, sample size, planned conduct and statistical analyses are acceptable to support regulatory approval. Further, it provides assurance that these agreed measures will serve as the basis for regulatory review and the decision by the FDA to approve an NDA for LibiGel.
In addition to the two Phase III safety and efficacy trials covered by the SPA, BioSante is conducting one Phase III cardiovascular and breast cancer safety study of LibiGel, which also is underway. The safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular events and breast cancer study of between 2,750 and
4,000 women exposed to LibiGel or placebo. BioSante will follow the women enrolled in the safety study for a total of 5 years. However, after an average of 12 months' exposure BioSante intends to submit a LibiGel NDA for review and potential approval by FDA.
The LibiGel safety study is tracking a composite of cardiovascular events including cardiovascular death, myocardial infarction and stroke in women with FSD who are 50 years of age or older and have at least two cardiovascular risk factors such as hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of cardiovascular events. The incidence of breast cancer also will be tracked throughout the study.
BioSante has reported that in the first 2,750 women enrolled comprising approximately 2,700 women-years of exposure, there have been only 14 adjudicated cardiovascular events even though the safety study is enrolling women with a higher risk of cardiovascular events. To date, over 2,750 women have been enrolled.
BioSante's obective is to submit the LibiGel NDA in 2011 for a potential FDA approval in 2012.
Contact BioSante Pharmaceuticals
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220; azachary@mckinneychicago.com
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
To the extent any statements made in this news release deal with information that is not hist orical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Disclaimer: This news release is part of a monthly information distribution program for BioSante (BPAX) (one thousand dollars per month). Investorideas.com is a third party publisher of news and research .All information on featured companies is prepared by the company or taken from public filings and news releases. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
About InvestorIdeas.com :
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech/pharma, mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Visit our Biotech investor portal : www.biotechindustrystocks.com
Research more biotech stocks at the Biotech stocks Directory
Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante Pharmaceuticals Inc.
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411: cvanzant@investorideas.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
Wednesday, February 02, 2011
Green Car Stocks Update; EVCARCO Set to Implement Franchise Strategy, Ener1 Showcased for Innovation and Job Growth
Point Roberts WA- February 2, 2011 - Investorideas.com a leader in cleantech investor research reports on recent news in the green car stocks sector.
Recent Green Car News:
DALLAS, TX-- - 12/29/10 - EVCARCO Inc. (OTC.BB:EVCA) is pleased to announce that the Company has signed a three year executive agreement with Mr. Mack Sanders, who was recently appointed CEO by EVCARCO's board of directors. Mr. Sanders will be mainly responsible for the Company's roll out of its retail franchise model throughout the United States for its environmentally friendly vehicle product line as well as overseeing the day to day operations of the Company.
Mr. Sanders comes to EVCARCO with a strong background in the retail and wholesale automotive industry working in retail locations for Lincoln Mercury, Oldsmobile, and Mercedes. Mr. Sanders started his professional career in 1982 working as a retail sales professional for Pioneer Lincoln Mercury in Lubbock, Texas for their pre-owned vehicle division. Mr. Sanders played a key role in the 1980s in helping develop and maintain the pre-owned vehicle retail locations for Giles Volvo in Houston, Texas. After moving back to Dallas in 1990, Mr. Sanders entered the dealer to dealer automotive wholesale business permanently, working for over 15 years with David Jurecki where to this day, Mr. Sanders has cultivated long standing accounts with automotive franchise owners throughout the country.
"I am excited to join EVCARCO and bring my knowledge and expertise in the retail and wholesale operations, inventory management and new car franchise business, which will enable EVCARCO to build its own franchise brand for environmentally friendly dealerships," stated Mack Sanders, CEO of EVCARCO.
"Mack Sanders brings a strong history of automotive expertise to our management team, which will enable us to quickly achieve key milestones in 2011," stated Nikolay Frolov, Chief Financial Officer and Director of EVCARCO.
About EVCARCO
EVCARCO (www.evcarco.com) is an automotive retail group dedicated to deploying a franchised coast-to-coast network of environmentally friendly dealerships and vehicles.
Ener1 (Nasdaq:HEV ) Showcased for Innovation and Job Growth
Vice President Joe Biden Visits Company's Battery Pack Assembly Plant
Announces Large-Scale Government Program to Spur Electric Vehicle Deployment
GREENFIELD, Ind., Jan. 26, 2011 -- Ener1, Inc. (Nasdaq:HEV ) provided a backdrop today for remarks by Vice President Joe Biden on the administration's continued commitment to asserting U.S. leadership in the advanced vehicle industry, a centerpiece of White House economic and environmental policy.
"As the president said last night, by 2015 we will have one million electric vehicles on the road," Biden said, referring to President Barack Obama's State of the Union address last night. "Once America has set a goal as a nation, we have never, never not achieved it," the vice president told Ener1's 350 Indiana employees and invited guests during a presentation at the company's Mt. Comfort plant.
The vice president visited Ener1, a leading manufacturer of advanced lithium-ion batteries, to witness the company's progress since receiving a $118.5 million federal stimulus grant in 2009. Biden commended Ener1 for its success in leveraging federal funds to attract private capital, in creating hundreds of new jobs for automotive industry workers and contributing to U.S. innovation in electric-drive technology.
The vice president also seized the occasion to announce a new federal program to accelerate the wide-scale adoption of electric vehicles. Under the proposed initiative included in the president's upcoming budget, 30 deployment communities, cities and towns across America, would be selected on a competitive basis for federal grants to support financial incentives for car purchases and charging infrastructure development, among other measures. The president is also asking for an almost 90-percent funding increase to nearly $590 million for advanced vehicle technologies.
Biden was introduced by Ener1 battery assembly line worker Wendy Howard, supported in the audience by her three sons and father. Before joining Ener1, Howard was downsized out of a job assembling pumps for power steering systems at a failing automotive plant. "Now I make these hi-tech batteries for electric cars that don't disturb the environment and don't drink up oil that we don't have."
Ener1, a principal investor in the dedicated electric vehicle manufacturer THINK™, had several cars on display at the event and demonstrated a two-seat urban commuter model for the vice president. The THINK City vehicle, which went on sale in the U.S. in December, is manufactured in the city of Elkhart, Ind. President Obama selected Elkhart in 2009 to announce $2.4 billion in electric-drive grants, the single-largest investment in advanced battery manufacturing in American history.
"The honor of being paid a visit by the vice president of the United States at our plant, and of being the site of an announcement of this magnitude for the nascent electric drive industry, is truly a reward for hard work," commented Ener1 Chairman and CEO Charles Gassenheimer. "The employees of our company certainly all deserve it."
About Ener1, Inc. (Nasdaq:HEV )
Ener1, Inc. is a publicly traded (Nasdaq:HEV ) energy technology company that develops compact, lithium-ion-powered battery solutions for the transportation, utility grid storage and consumer markets. Headquartered in New York City, the company has more than 700 employees with manufacturing locations in the United States and Korea. Ener1 also develops commercial fuel cell products, nanotechnology-based materials and manufacturing processes. In collaboration with strategic partner and electric vehicle manufacturer THINK, Ener1 also manufactures electric vehicle drive train products.
Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
Research other green stocks with the renewable energy stocks directory; a global stock directory featuring over 1300 green stocks. Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/
About Our Green Investor content:
Visit our showcase green stocks and research green stocks at: www.renewableenergystocks.com and http://www.investorideas.com/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector investing content. Investor Ideas (and portals within the hub) was one of the first online investing and business resources providing in-depth information, news and stock directories in renewable energy, homeland security and water sectors. InvestorIdeas.com features over twenty industry sectors and global markets including China, India, Middle East and Australia.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: EVCA is a previous advertising client on Investorideas.com and compensated Investorideas.com 500,000 144 shares in lieu of cash fees.
800-665-0411 - dvanzant@investorideas.com
Source – Investorideas.com
Investor Tools for Trading Energy Stocks as Oil Trades over $91
POINT ROBERTS, Wash., February 2 , 2011 - www.InvestorIdeas.com, a global
investor research portal, specializing in sector research including energy stocks,
updates investors with content and stock directories to research the oil and gas
sector as energy stocks and oil prices rise.
The oil and gas stocks directory features over seven hundred stocks listed on the
TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading
Stock Exchanges. The directory also features a section on Bakken stocks and oil
sands stocks.
Preview the directory here: http://www.investorideas.com/OGSN/Stock_List.asp
The energy stocks directory is available separately in a PDF of part of the
Investorideas.com Members currently have 24/7 online access to the exclusive
subscriber-only eleven stock directories in leading sectors including renewable
energy, water, mining, defense, biotech, nanotech and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
Investors can follow news and developments in energy stocks with the
syndicated energy stocks newswire, featuring commentary from energy expert
Karl Miller. Investors can subscribe for free to the RSS at
http://www.investorideas.com/RSS/feeds/Energy.xml .
Additional energy stocks research tools:
Natural Gas Stocks Directory - Global Directory of Publicly traded Natural Gas
Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The directory includes small cap,
micro cap as well as large cap NYSE listed stocks for review. Natural gas stocks
included range from LNG, Coal Bed Methane to exploration and producers in
the sector. The directory in PDF format, features hyperlinks to stocks symbol(s),
company's URL and company's description.
Oil and Gas Stocks Directory Preview
.
American Petro-Hunter, Inc. (OTCBB: AAPH) is a goal-oriented exploration and production
(E&P) Company aiming to become an intermediate level oil and gas producer within 12 months.
The Company is in production at the Poston Project in Trego County Kansas with new drilling
activity and production underway at the North Oklahoma Oil Project. With the achievable target of
becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for
domestic petroleum assets.
Aroway Minerals Inc. (TSX.V: ARW) is junior oil and gas exploration Company focused on high
working interest non-operated oil and gas exploration prospects. Aroway is currently participating
in two exploration wells which are programmed to a total depth into the Leduc formation in the
Peace River Arch area of Alberta. The Company will pay 75% of all costs to earn 50% of all
revenues in the exploration program.
* Stocks are showcase advertising water companies on our site - Read disclaimers and
Disclosure
3D Oil Limited (ASX.TSO.AX) is an oil and gas exploration company. The company holds 100%
equity in two permits in Bass Strait; Vic/P57 in the Gippsland basin, Victoria and T41-P in the
Bass basin, Tasmania.
Abraxas Petroleum Corporation (NasdaqCM:AXAS) is a San Antonio based crude oil and
natural gas exploration and production company with operations principally in Texas, the Mid-
Continent and the Rocky Mountains. Abraxas Petroleum Corporation also owns a 47% interest in
an upstream master limited partnership, Abraxas Energy Partners, L.P., which entitles Abraxas
Petroleum Corporation to receive its proportionate share of cash distributions made by the
Partnership.
Abu Dhabi National Energy Company PJSC (ADX: TAQA.AE) is a global energy company with
operations in power generation, water desalination, upstream oil/gas, pipelines and gas storage.
In addition to supplying more than 98% of power in its domestic market, TAQA is expanding its
footprint across the Middle East, The Americas and Europe. It is one of the largest companies
listed on the ADX. TAQA has around 2,800 employees and operates from its offices in Abu
Dhabi, Michigan, Aberdeen, Calgary, Amsterdam and The Hague with alliance partners across
the Gulf, Middle East, North Africa, Europe, Asia, and the United States. TAQA carries an AA-
credit rating according to internationally renowned rating agency S&P and Aa2 by Moody's.
Acergy S.A (NasdaqGS: ACGY; Oslo:ACY.OL) is a seabed-to-surface engineering and
construction contractor to the offshore oil and gas industry worldwide. We provide integrated
services, and we plan, design and deliver complex projects in harsh and challenging
environments.
ACT Clean Technologies, Inc. (OTCPK:ACLH) is committed to both a safer environment through
cleaner technologies as well as more profitable methods of oil recovery and production from oil
sands and other petroleum reserves. APS clients who have used its technologies include some
of the largest oil and gas companies in the United States, including Conoco Phillips, Exxon Mobil,
Avon Petroleum, Valero Petroleum, BP (British Petroleum) as well as the US Navy Petroleum
Reserve.
ACTIVENERGY INCOME TRUST UNITS (AEU-UN.TO) is a TSX listed closed-end investment
fund that invests in a diversified portfolio of energy companies with an emphasis on oil and gas as
well as common shares of Canadian and U.S.-based issuers operating in the energy sector.
Adams Resources And Energy (AMEX:AE) together with its subsidiaries, engages in marketing
crude oil, natural gas, and petroleum products. It purchases crude oil, and arranges sales and
deliveries to refiners and other customers in Texas and Louisiana with additional operations
in Michigan and New Mexico; and purchases, distributes, and markets natural gas, as well as
markets branded and unbranded refined petroleum products, such as motor fuels, including
automotive gasoline, biodiesel, and conventional diesel fuel; and lubricants, including passenger
car motor oils, and industrial oils and greases. The company also engages in the exploration,
development, and production of domestic oil and natural gas properties in Louisiana and Texas
Gulf Coast. As of December 31, 2008, the company held interest in 323 wells.
Addax Petroleum Corporation (TSX:AXC.TO) is an international oil and gas exploration and
production company with a strategic focus on West Africa and the Middle East. Nigeria's natural
gas reserves are estimated by the Nigerian National Petroleum Corporation (NNPC) to be 187
Tcf in 2006, ranking Nigeria to be the seventh largest natural gas reserves holder in the world.
To date this resource has been underdeveloped due to the primary focus of the industry on oil
resource development for export. However, now the Nigerian government has announced its
objective to increase natural gas revenue sales and secure flares down for all operations.
Adelaide Energy Limited (ASX:ADE.AX) is focused on oil and gas exploration in the Cooper and
Otway Basins of SA and the West Florence Basin of Colorado, USA.
Adelphi Energy Limited (ASX:ADI.AX) is an ASX listed Australian based petroleum exploration
company with a focus on pursuing and acquiring high impact oil and gas exploration and
production opportunities. It currently holds exploration permits in the USA and Yemen.
Preview and access the full directory of over 600 stocks here: http://
www.investorideas.com/OGSN/Stock_List.asp
Sign up for the free investor news letter and get stock alerts in leading
sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector
investing content.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no
guarantees as to the accuracy of information presented. All Information relating to featured companies is
sourced from public documents and/ or the company and is not the opinion of our web sites. This site is
currently compensated by featured companies, news submissions and online advertising. Disclosure
AAPH and ARW are advertising showcase energy stocks and pay Investorideas.com an average of $2000
per month .
More:www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue
partner:
800-665-0411 - cvanzant@investorideas.com
Source – Investorideas.com
POINT ROBERTS, Wash., February 2 , 2011 - www.InvestorIdeas.com, a global
investor research portal, specializing in sector research including energy stocks,
updates investors with content and stock directories to research the oil and gas
sector as energy stocks and oil prices rise.
The oil and gas stocks directory features over seven hundred stocks listed on the
TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading
Stock Exchanges. The directory also features a section on Bakken stocks and oil
sands stocks.
Preview the directory here: http://www.investorideas.com/OGSN/Stock_List.asp
The energy stocks directory is available separately in a PDF of part of the
Investorideas.com Members currently have 24/7 online access to the exclusive
subscriber-only eleven stock directories in leading sectors including renewable
energy, water, mining, defense, biotech, nanotech and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
Investors can follow news and developments in energy stocks with the
syndicated energy stocks newswire, featuring commentary from energy expert
Karl Miller. Investors can subscribe for free to the RSS at
http://www.investorideas.com/RSS/feeds/Energy.xml .
Additional energy stocks research tools:
Natural Gas Stocks Directory - Global Directory of Publicly traded Natural Gas
Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The directory includes small cap,
micro cap as well as large cap NYSE listed stocks for review. Natural gas stocks
included range from LNG, Coal Bed Methane to exploration and producers in
the sector. The directory in PDF format, features hyperlinks to stocks symbol(s),
company's URL and company's description.
Oil and Gas Stocks Directory Preview
.
American Petro-Hunter, Inc. (OTCBB: AAPH) is a goal-oriented exploration and production
(E&P) Company aiming to become an intermediate level oil and gas producer within 12 months.
The Company is in production at the Poston Project in Trego County Kansas with new drilling
activity and production underway at the North Oklahoma Oil Project. With the achievable target of
becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for
domestic petroleum assets.
Aroway Minerals Inc. (TSX.V: ARW) is junior oil and gas exploration Company focused on high
working interest non-operated oil and gas exploration prospects. Aroway is currently participating
in two exploration wells which are programmed to a total depth into the Leduc formation in the
Peace River Arch area of Alberta. The Company will pay 75% of all costs to earn 50% of all
revenues in the exploration program.
* Stocks are showcase advertising water companies on our site - Read disclaimers and
Disclosure
3D Oil Limited (ASX.TSO.AX) is an oil and gas exploration company. The company holds 100%
equity in two permits in Bass Strait; Vic/P57 in the Gippsland basin, Victoria and T41-P in the
Bass basin, Tasmania.
Abraxas Petroleum Corporation (NasdaqCM:AXAS) is a San Antonio based crude oil and
natural gas exploration and production company with operations principally in Texas, the Mid-
Continent and the Rocky Mountains. Abraxas Petroleum Corporation also owns a 47% interest in
an upstream master limited partnership, Abraxas Energy Partners, L.P., which entitles Abraxas
Petroleum Corporation to receive its proportionate share of cash distributions made by the
Partnership.
Abu Dhabi National Energy Company PJSC (ADX: TAQA.AE) is a global energy company with
operations in power generation, water desalination, upstream oil/gas, pipelines and gas storage.
In addition to supplying more than 98% of power in its domestic market, TAQA is expanding its
footprint across the Middle East, The Americas and Europe. It is one of the largest companies
listed on the ADX. TAQA has around 2,800 employees and operates from its offices in Abu
Dhabi, Michigan, Aberdeen, Calgary, Amsterdam and The Hague with alliance partners across
the Gulf, Middle East, North Africa, Europe, Asia, and the United States. TAQA carries an AA-
credit rating according to internationally renowned rating agency S&P and Aa2 by Moody's.
Acergy S.A (NasdaqGS: ACGY; Oslo:ACY.OL) is a seabed-to-surface engineering and
construction contractor to the offshore oil and gas industry worldwide. We provide integrated
services, and we plan, design and deliver complex projects in harsh and challenging
environments.
ACT Clean Technologies, Inc. (OTCPK:ACLH) is committed to both a safer environment through
cleaner technologies as well as more profitable methods of oil recovery and production from oil
sands and other petroleum reserves. APS clients who have used its technologies include some
of the largest oil and gas companies in the United States, including Conoco Phillips, Exxon Mobil,
Avon Petroleum, Valero Petroleum, BP (British Petroleum) as well as the US Navy Petroleum
Reserve.
ACTIVENERGY INCOME TRUST UNITS (AEU-UN.TO) is a TSX listed closed-end investment
fund that invests in a diversified portfolio of energy companies with an emphasis on oil and gas as
well as common shares of Canadian and U.S.-based issuers operating in the energy sector.
Adams Resources And Energy (AMEX:AE) together with its subsidiaries, engages in marketing
crude oil, natural gas, and petroleum products. It purchases crude oil, and arranges sales and
deliveries to refiners and other customers in Texas and Louisiana with additional operations
in Michigan and New Mexico; and purchases, distributes, and markets natural gas, as well as
markets branded and unbranded refined petroleum products, such as motor fuels, including
automotive gasoline, biodiesel, and conventional diesel fuel; and lubricants, including passenger
car motor oils, and industrial oils and greases. The company also engages in the exploration,
development, and production of domestic oil and natural gas properties in Louisiana and Texas
Gulf Coast. As of December 31, 2008, the company held interest in 323 wells.
Addax Petroleum Corporation (TSX:AXC.TO) is an international oil and gas exploration and
production company with a strategic focus on West Africa and the Middle East. Nigeria's natural
gas reserves are estimated by the Nigerian National Petroleum Corporation (NNPC) to be 187
Tcf in 2006, ranking Nigeria to be the seventh largest natural gas reserves holder in the world.
To date this resource has been underdeveloped due to the primary focus of the industry on oil
resource development for export. However, now the Nigerian government has announced its
objective to increase natural gas revenue sales and secure flares down for all operations.
Adelaide Energy Limited (ASX:ADE.AX) is focused on oil and gas exploration in the Cooper and
Otway Basins of SA and the West Florence Basin of Colorado, USA.
Adelphi Energy Limited (ASX:ADI.AX) is an ASX listed Australian based petroleum exploration
company with a focus on pursuing and acquiring high impact oil and gas exploration and
production opportunities. It currently holds exploration permits in the USA and Yemen.
Preview and access the full directory of over 600 stocks here: http://
www.investorideas.com/OGSN/Stock_List.asp
Sign up for the free investor news letter and get stock alerts in leading
sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector
investing content.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no
guarantees as to the accuracy of information presented. All Information relating to featured companies is
sourced from public documents and/ or the company and is not the opinion of our web sites. This site is
currently compensated by featured companies, news submissions and online advertising. Disclosure
AAPH and ARW are advertising showcase energy stocks and pay Investorideas.com an average of $2000
per month .
More:www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue
partner:
800-665-0411 - cvanzant@investorideas.com
Source – Investorideas.com
Consumer/ Retail Stocks; YesDTC and Medical Alarm Concepts Experience Successful Infomercial Campaign Test in Multi-Million Dollar Segment
SAN FRANCISCO - February 2, 2011 (Investorideas.com newswire) � YesDTC Holdings, Inc. (OTCBB:YESD) and Medical Alarm Concepts Holdings, Inc. (OTCBB:MDHI) today announced the completion of a highly successful direct response television marketing test, conducted by the joint venture between the two companies, to market and sell the MediPendant(TM) personal medical alarm system. MediPendant is the only personal medical alarm on the market that enables the user to speak and listen through the pendant. The MediPendant television advertisement can be viewed at www.medipendant.com
The direct response television marketing test was conducted over the past few weeks, with one additional week still pending. Both companies believe the results to date have been impressive. Over the expected life of the customer contracts sold during the first week of the test, the return on advertising expenditures was 284%, with a substantial number of new customers electing to pay for the entire contract up front. Similar favorable test results have been generated during subsequent weeks of the test and are currently expected to continue going forward.
"From these results, it is very clear that MediPendant is a viable product offering via direct response television. We plan to increase media expenditures over the coming weeks," commented Howard Teicher, CEO of Medical Alarm Concepts. "The turn around in this campaign was the decision to bring the call center sales function in house. This lowered our costs and, more importantly, increased sales closure rates as a result of being able to have our own highly trained operators handle the sales function. We could not be more pleased with the way this campaign is progressing." He continued, "We are expecting to close more than 100 orders during the few weeks of the test period. Considering the very limited advertising expenditures involved, this order level is significant. As we ramp the media spend over the coming weeks, we believe a substantial and fast growing profitable revenue stream can be obtained for both Medical Alarm Concepts and YesDTC Holdings."
Joseph Noel, CEO of YesDTC commented, "The personal medical alarm space is a proven one that generates tens of millions of dollars per month. The entrenched competitor, famous for the "I've fallen and I can't get up" campaign, showed that the direct response format works well for this product category. Fortunately for us and for Medical Alarm Concepts, its technology, which features the industry's only pendant that allows for two-way communication through the pendant, is vastly superior to other devices in the market place today. All of us at YesDTC continue to be excited about how this campaign is progressing."
Medical Alarms Concepts is the manufacturer of the MediPendant(TM) product, a patented medical emergency alert system that includes several revolutionary and highly desirable features, including direct through-the-pendant speak-and-listen capability, the ability to allow the conferencing of third party contacts while on an emergency call, and an extended product operating range that enables users to move up to 600+ feet (line of sight) from the base station. The Company's media campaign partner, YesDTC, is a direct-to-consumer global distributor and marketer of consumer goods and products. As part of its strategy to market and sell innovative consumer products via customized DRTV campaigns, YesDTC maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
lists
and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising .
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
SAN FRANCISCO - February 2, 2011 (Investorideas.com newswire) � YesDTC Holdings, Inc. (OTCBB:YESD) and Medical Alarm Concepts Holdings, Inc. (OTCBB:MDHI) today announced the completion of a highly successful direct response television marketing test, conducted by the joint venture between the two companies, to market and sell the MediPendant(TM) personal medical alarm system. MediPendant is the only personal medical alarm on the market that enables the user to speak and listen through the pendant. The MediPendant television advertisement can be viewed at www.medipendant.com
The direct response television marketing test was conducted over the past few weeks, with one additional week still pending. Both companies believe the results to date have been impressive. Over the expected life of the customer contracts sold during the first week of the test, the return on advertising expenditures was 284%, with a substantial number of new customers electing to pay for the entire contract up front. Similar favorable test results have been generated during subsequent weeks of the test and are currently expected to continue going forward.
"From these results, it is very clear that MediPendant is a viable product offering via direct response television. We plan to increase media expenditures over the coming weeks," commented Howard Teicher, CEO of Medical Alarm Concepts. "The turn around in this campaign was the decision to bring the call center sales function in house. This lowered our costs and, more importantly, increased sales closure rates as a result of being able to have our own highly trained operators handle the sales function. We could not be more pleased with the way this campaign is progressing." He continued, "We are expecting to close more than 100 orders during the few weeks of the test period. Considering the very limited advertising expenditures involved, this order level is significant. As we ramp the media spend over the coming weeks, we believe a substantial and fast growing profitable revenue stream can be obtained for both Medical Alarm Concepts and YesDTC Holdings."
Joseph Noel, CEO of YesDTC commented, "The personal medical alarm space is a proven one that generates tens of millions of dollars per month. The entrenched competitor, famous for the "I've fallen and I can't get up" campaign, showed that the direct response format works well for this product category. Fortunately for us and for Medical Alarm Concepts, its technology, which features the industry's only pendant that allows for two-way communication through the pendant, is vastly superior to other devices in the market place today. All of us at YesDTC continue to be excited about how this campaign is progressing."
Medical Alarms Concepts is the manufacturer of the MediPendant(TM) product, a patented medical emergency alert system that includes several revolutionary and highly desirable features, including direct through-the-pendant speak-and-listen capability, the ability to allow the conferencing of third party contacts while on an emergency call, and an extended product operating range that enables users to move up to 600+ feet (line of sight) from the base station. The Company's media campaign partner, YesDTC, is a direct-to-consumer global distributor and marketer of consumer goods and products. As part of its strategy to market and sell innovative consumer products via customized DRTV campaigns, YesDTC maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock http://www.investorideas.com/Resources/Newsletter.asp
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. To Provide Update on LibiGel Safety Study at International Society for the Study of Women's Sexual Health Meeting
LINCOLNSHIRE, Ill. - February 2, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it will provide a LibiGel safety study update, and is supporting two clinical symposia at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH) being held from February 10-13, 2011 at the Doubletree Paradise Valley resort in Scottsdale, Arizona. More than 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting.
Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, will deliver an oral presentation entitled, "LibiGel� (testosterone gel) Safety Study Continues with a Low Rate of Cardiovascular and Breast Cancer Events," on February 12, 2011 at 3 pm local time. Dr. Snabes will provide an update on the largest-ever safety study comparing low-dose testosterone treatment to placebo treatment, including the LibiGel safety study's low cardiovascular event rate. To date, this ongoing study has enrolled more than 2,800 menopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD).
The supported symposia are entitled, "Efficacy of Testosterone in Treating Women with HSDD" and "FSD and the FDA: Past, Present & Future." The first symposium, "Efficacy of Testosterone in Treating Women with HSDD," will feature Susan R. Davis, MBBS, FRACP, PhD, Professor of Women's Health and NHMRC Principal Research Fellow and Director, the Women's Health Research Program, Department of Medicine, Monash University, Vic, Australia, and Glenn Braunstein, MD, Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
The second symposium, "FSD and the FDA: Past, Present & Future," will be moderated by Alan Altman, MD, president of ISSWSH. The speakers include Anita H. Clayton, MD, professor of psychiatry and neurobehavioral sciences, and professor of clinical obstetrics and gynecology at the University of Virginia Health Systems; Michael Krychman, MD, medical director of The Sexual Medicine Center in Hoag Hospital in Newport Beach, California; Marianne Brandon, PhD, a clinical psychologist for Wellminds Wellbodies LLC and a diplomat in sex therapy; Julia Heiman, PhD, director of the Kinsey Institute for Research in Sex, Gender, and Reproduction and professor of psychology and clinical psychiatry at Indiana University, as well as Dr. Snabes of BioSante.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and DrugAdministration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market size, acceptance and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
LINCOLNSHIRE, Ill. - February 2, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it will provide a LibiGel safety study update, and is supporting two clinical symposia at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH) being held from February 10-13, 2011 at the Doubletree Paradise Valley resort in Scottsdale, Arizona. More than 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting.
Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, will deliver an oral presentation entitled, "LibiGel� (testosterone gel) Safety Study Continues with a Low Rate of Cardiovascular and Breast Cancer Events," on February 12, 2011 at 3 pm local time. Dr. Snabes will provide an update on the largest-ever safety study comparing low-dose testosterone treatment to placebo treatment, including the LibiGel safety study's low cardiovascular event rate. To date, this ongoing study has enrolled more than 2,800 menopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD).
The supported symposia are entitled, "Efficacy of Testosterone in Treating Women with HSDD" and "FSD and the FDA: Past, Present & Future." The first symposium, "Efficacy of Testosterone in Treating Women with HSDD," will feature Susan R. Davis, MBBS, FRACP, PhD, Professor of Women's Health and NHMRC Principal Research Fellow and Director, the Women's Health Research Program, Department of Medicine, Monash University, Vic, Australia, and Glenn Braunstein, MD, Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
The second symposium, "FSD and the FDA: Past, Present & Future," will be moderated by Alan Altman, MD, president of ISSWSH. The speakers include Anita H. Clayton, MD, professor of psychiatry and neurobehavioral sciences, and professor of clinical obstetrics and gynecology at the University of Virginia Health Systems; Michael Krychman, MD, medical director of The Sexual Medicine Center in Hoag Hospital in Newport Beach, California; Marianne Brandon, PhD, a clinical psychologist for Wellminds Wellbodies LLC and a diplomat in sex therapy; Julia Heiman, PhD, director of the Kinsey Institute for Research in Sex, Gender, and Reproduction and professor of psychology and clinical psychiatry at Indiana University, as well as Dr. Snabes of BioSante.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market size, acceptance and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
Oil and Gas News; TAG Oil Begins Drilling Sidewinder-2: First in Series for New Discovery
Vancouver , B.C. - February 2, 2011 (Investorideas.com Newswire)- Canadian listed, New Zealand oil and gas producer TAG Oil Ltd. (TSX-V: TAO), announced that the Sidewinder-2 well is scheduled to begin drilling operations on February 7, 2011.
This is the first of several appraisal and exploration wells to be drilled in the 7910-acre (12 section), 100% TAG-controlledPetroleum Exploration Permit 38748 ("PEP 38748") in New Zealand's Taranaki Basin.
Following the success of the gas-rich Sidewinder-1 discovery, the Sidewinder-2 and 3 wells will be drilled to a depth of approximately 2400 meters, targeting the same Mt. Messenger Formation play level as Sidewinder-1. However, these wells will be drilled in a slightly downdip location to intersect an interpreted "oil leg" associated with this proven accumulation.
TAG also announces its plans to conduct a multi-well, high-impact exploration campaign in PEP 38748 targeting a number of Mt. Messenger prospects similar to Sidewinder, that have been identified permit-wide by 3D seismic.
Any successes arising from additional discoveries in PEP 38748 or additional Sidewinder production wells will be immediately tied into the Sidewinder Production Station. Currently under construction, TAG forecasts completion of the new facility by mid-2011.
Production from the existing Sidewinder-1 well, forecast to produce at rates of 8 to 10 million cubic feet of gas (1300 to 1600 barrels of oil equivalent) per day, will be brought on stream upon completion of the Sidewinder Production Station.
Please see http://tagoil.com/20101103-TAG-Oil-Announces-Strong-Results-at-Sidewinder-1-Flow-T.asp for more information on the Sidewinder-1 discovery.
TAG Oil Ltd.
TAG Oil Ltd. is a Canadian-listed company (TSX-V: TAO) with operations in New Zealand. With 100% control of its core assets, including oil and gas production infrastructure, TAG is anticipating production growth through development of multiple oil and gas discoveries in the Taranaki Basin. TAG is also targeting high-impact drilling opportunities on numerous exploration prospects identified over 3,500 sections of land onshore.
In the East Coast Basin, TAG is pursuing the major unconventional resource potential that has been demonstrated in the Waipawa Black Shale and Whangai Shale source-rock formations. These oil-rich, naturally fractured formations compare favorably to fractured shale formations such as the Bakken Shale in the Williston Basin.
Contact:
Dan Brown or Garth Johnson, TAG Oil Ltd. 1-604-682-6496
Website: http://www.tagoil.com/
"BOE"s may be misleading, particularly if used in isolation. A BOE conversion ratio of 6Mcf: 1 Bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this news release that are not historical facts are forward-looking statements that involve various risks and uncertainty affecting the business of TAG Oil. These statements are based on certain factors and assumptions including those related to the exploration, development and daily production rates of TAG Oil's Cheal oil field and Sidewinder discovery in the Taranaki Basin of New Zealand. Actual results may vary materially from the information provided in this release and there is no representation by TAG Oil that actual results realized in the future would be the same in whole or in part as those presented herein.
Factors that could cause actual results to differ from those contained in the forward-looking statements are set forth in, but are not limited to, filings that the Company and its independent evaluator have made, including the Company's most recent reports inCanada under National Instrument 51-101.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This is the first of several appraisal and exploration wells to be drilled in the 7910-acre (12 section), 100% TAG-controlled
Following the success of the gas-rich Sidewinder-1 discovery, the Sidewinder-2 and 3 wells will be drilled to a depth of approximately 2400 meters, targeting the same Mt. Messenger Formation play level as Sidewinder-1. However, these wells will be drilled in a slightly downdip location to intersect an interpreted "oil leg" associated with this proven accumulation.
TAG also announces its plans to conduct a multi-well, high-impact exploration campaign in PEP 38748 targeting a number of Mt. Messenger prospects similar to Sidewinder, that have been identified permit-wide by 3D seismic.
Any successes arising from additional discoveries in PEP 38748 or additional Sidewinder production wells will be immediately tied into the Sidewinder Production Station. Currently under construction, TAG forecasts completion of the new facility by mid-2011.
Production from the existing Sidewinder-1 well, forecast to produce at rates of 8 to 10 million cubic feet of gas (1300 to 1600 barrels of oil equivalent) per day, will be brought on stream upon completion of the Sidewinder Production Station.
Please see http://tagoil.com/20101103-TAG-Oil-Announces-Strong-Results-at-Sidewinder-1-Flow-T.asp for more information on the Sidewinder-1 discovery.TAG Oil Ltd.
TAG Oil Ltd. is a Canadian-listed company (TSX-V: TAO) with operations in New Zealand. With 100% control of its core assets, including oil and gas production infrastructure, TAG is anticipating production growth through development of multiple oil and gas discoveries in the Taranaki Basin. TAG is also targeting high-impact drilling opportunities on numerous exploration prospects identified over 3,500 sections of land onshore.
In the East Coast Basin, TAG is pursuing the major unconventional resource potential that has been demonstrated in the Waipawa Black Shale and Whangai Shale source-rock formations. These oil-rich, naturally fractured formations compare favorably to fractured shale formations such as the Bakken Shale in the Williston Basin.
Contact:
Dan Brown or Garth Johnson, TAG Oil Ltd. 1-604-682-6496
Website: http://www.tagoil.com/
"BOE"s may be misleading, particularly if used in isolation. A BOE conversion ratio of 6Mcf: 1 Bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this news release that are not historical facts are forward-looking statements that involve various risks and uncertainty affecting the business of TAG Oil. These statements are based on certain factors and assumptions including those related to the exploration, development and daily production rates of TAG Oil's Cheal oil field and Sidewinder discovery in the Taranaki Basin of New Zealand. Actual results may vary materially from the information provided in this release and there is no representation by TAG Oil that actual results realized in the future would be the same in whole or in part as those presented herein.
Factors that could cause actual results to differ from those contained in the forward-looking statements are set forth in, but are not limited to, filings that the Company and its independent evaluator have made, including the Company's most recent reports in
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Tuesday, February 01, 2011
Security Stocks; Visualant Subsidiary TransTech Announces $1.2 Million Contract
Seattle, WA - February 1, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), an emerging leader in authentication systems technology, announced today its wholly owned subsidiary, TransTech Systems, Inc. of Aurora, OR was awarded a contract in the amount of $1.2 Million.
The contract from one of the 38 NASA SEWP (Solutions for Enterprise-Wide Procurement) GWAC (Government-Wide Acquisition Contract) designated prime contractors is an extension of a contract first awarded to TransTech two years ago and is testimony to the satisfaction both with TransTech�s performance and the quality of the printers provided under this initial contract. These high end printers provide the digital high security identification cards required by a 2004 Presidential directive.
Jim Gingo, TransTech President said, "We are pleased to be selected for this continuation contract. We work hard to maintain quality relationships and strive for excellence with both our vendors and our customers."
About Visualant, Inc.
Visualant, Inc. develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Its patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching (SPM). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the UnitedStates .
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements (within the meaning of Section 27a of the Securities Act of 1933 and Section 21e of the Securities Exchange Act of 1934) regarding us and our business, financial condition, results of operations and prospects. Forward-looking statements in this press release reflect the good faith judgment of our management and are based on facts and factors currently known to us. Forward-looking statements are subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements as a result of either the matters set forth or incorporated in this press release generally or certain economic and business factors, some of which may be unknown to and/or beyond the control of Visualant, Inc.. Specifically, we are exposed to various risks related to our revenue projections, our need for additional financing to support our technology development, acquiring or investing in new businesses and ongoing operations, the sale of a significant number of our shares of common stock could depress the price of our common stock, the market price of our common stock may be volatile, and we may incur losses in the future. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We do not undertake, and we expressly disclaim, any obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of the press release.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Seattle, WA - February 1, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), an emerging leader in authentication systems technology, announced today its wholly owned subsidiary, TransTech Systems, Inc. of Aurora, OR was awarded a contract in the amount of $1.2 Million.
The contract from one of the 38 NASA SEWP (Solutions for Enterprise-Wide Procurement) GWAC (Government-Wide Acquisition Contract) designated prime contractors is an extension of a contract first awarded to TransTech two years ago and is testimony to the satisfaction both with TransTech�s performance and the quality of the printers provided under this initial contract. These high end printers provide the digital high security identification cards required by a 2004 Presidential directive.
Jim Gingo, TransTech President said, "We are pleased to be selected for this continuation contract. We work hard to maintain quality relationships and strive for excellence with both our vendors and our customers."
About Visualant, Inc.
Visualant, Inc. develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Its patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching (SPM). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements (within the meaning of Section 27a of the Securities Act of 1933 and Section 21e of the Securities Exchange Act of 1934) regarding us and our business, financial condition, results of operations and prospects. Forward-looking statements in this press release reflect the good faith judgment of our management and are based on facts and factors currently known to us. Forward-looking statements are subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements as a result of either the matters set forth or incorporated in this press release generally or certain economic and business factors, some of which may be unknown to and/or beyond the control of Visualant, Inc.. Specifically, we are exposed to various risks related to our revenue projections, our need for additional financing to support our technology development, acquiring or investing in new businesses and ongoing operations, the sale of a significant number of our shares of common stock could depress the price of our common stock, the market price of our common stock may be volatile, and we may incur losses in the future. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We do not undertake, and we expressly disclaim, any obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of the press release.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs. Starting Nov 24th, 3 months (4000 per month by third party)
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs. Starting Nov 24th, 3 months (4000 per month by third party)
Coal Stocks News; Lucky Strike Resources; UPDATE ON FINANCING AND ACQUISITIONS
Vancouver, BritishColumbia , Canada - February 1, 2011 (Investorideas.com Newswire)- Lucky Strike Resources Ltd. (TSX.V: LKY), (the "Company") wishes to provide an update on its private placement announced on December 7, 2010 and on its proposed acquisition of the Changyun Coal mine as announced on August 10, 2010.
The Company wishes to clarify the intended use of the proceeds from the proposed non-brokered private placement to raise aggregate gross proceeds to the Company of $2,400,000 by the issuance of units of the Company, as previously announced on December 7, 2010. The net proceeds of the private placement will be used for general working capital purposes and to identify, evaluate and secure potential acquisitions of mineral properties and mineral interests inChina and internationally. The proceeds of the private placement are not specifically designated for any particular project at this time. The closing of the private placement is expected to occur on or before February 4, 2011.
On August 10, 2010 and October 29, 2010, the Company announced that it had entered into a letter of intent (the "Letter of Intent") with Cheung Wan (Groups) Energy Development Limited for the proposed acquisition (the "Acquisition") by the Company of up to an 80% interest in the Changyun Coal project (the "Changyun Coal Project") in Guizhou Province, China. The Acquisition is subject to a number of conditions including due diligence and the negotiation and preparation of a definitive agreement. The Company continues to conduct due diligence on the Changyun Coal Project and the vendors, and is attempting to address all of the issues in its negotiations. The Letter of Intent was subsequently amended on October 26, 2010 and based on the Company"s due diligence, the structure and material terms of the Acquisition continue to be subject to ongoing discussions and negotiations. It is uncertain if or when the parties will be able to reach agreement on the material ! terms or structure of a transaction regarding the Changyun Coal Project or if a transaction will be completed at all. The Company will provide further updates when warranted.
The Company is concurrently continuing to investigate other potential property acquisitions and will provide further updates as and when the Company enters into any agreements with respect to same.
About Lucky Strike:
Lucky Strike Resources Ltd. is a Canada-based exploration stage company. The Company is engaged in the process of exploring and/or developing coal properties in Guizhou province in China. The Company also has property in Yreka, BritishColumbia , Canada. The Changyun coal project is a former past producing mine and is located some 25 km northeast of Bijie City in Guizhou province, approximately two hours north by air from Hong Kong. The permitted mine covers a total area of 2.0954 sq. km and is surrounded by approximately 20 sq. km of highly prospective exploration area, where available geological data supports the potential presence of significant coal resources of high quality Anthracite coal within the area. The local area has well established infrastructure for the Changyun project to resume production and coal buyers to pick up coal FOB at the mine site.
On behalf of Management
Lucky Strike Resources Ltd.
"Cathy Fong"
Cathy Fong, CEO & Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain certain "Forward-Looking Statements" within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time with the Toronto Venture Exchange, the British Columbia Securities Commission and the US Securities and Exchange Commission.
Twitter: www.twitter.com/luckystrikepr
Vancouver, British
The Company wishes to clarify the intended use of the proceeds from the proposed non-brokered private placement to raise aggregate gross proceeds to the Company of $2,400,000 by the issuance of units of the Company, as previously announced on December 7, 2010. The net proceeds of the private placement will be used for general working capital purposes and to identify, evaluate and secure potential acquisitions of mineral properties and mineral interests in
On August 10, 2010 and October 29, 2010, the Company announced that it had entered into a letter of intent (the "Letter of Intent") with Cheung Wan (Groups) Energy Development Limited for the proposed acquisition (the "Acquisition") by the Company of up to an 80% interest in the Changyun Coal project (the "Changyun Coal Project") in Guizhou Province, China. The Acquisition is subject to a number of conditions including due diligence and the negotiation and preparation of a definitive agreement. The Company continues to conduct due diligence on the Changyun Coal Project and the vendors, and is attempting to address all of the issues in its negotiations. The Letter of Intent was subsequently amended on October 26, 2010 and based on the Company"s due diligence, the structure and material terms of the Acquisition continue to be subject to ongoing discussions and negotiations. It is uncertain if or when the parties will be able to reach agreement on the material ! terms or structure of a transaction regarding the Changyun Coal Project or if a transaction will be completed at all. The Company will provide further updates when warranted.
The Company is concurrently continuing to investigate other potential property acquisitions and will provide further updates as and when the Company enters into any agreements with respect to same.
About Lucky Strike:
Lucky Strike Resources Ltd. is a Canada-based exploration stage company. The Company is engaged in the process of exploring and/or developing coal properties in Guizhou province in China. The Company also has property in Yreka, British
On behalf of Management
Lucky Strike Resources Ltd.
"Cathy Fong"
Cathy Fong, CEO & Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain certain "Forward-Looking Statements" within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time with the Toronto Venture Exchange, the British Columbia Securities Commission and the US Securities and Exchange Commission.
Twitter: www.twitter.com/luckystrikepr
Biotech/Pharma Stocks News; UV Flu Technologies to Become an Official Equipment Supplier to Hockey Canada
CENTERVILLE, MA � February 1, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company's athletic distributor, New England Sports Sales ("NESSI"), a national distributor of hockey and related athletic equipment to college and professional hockey teams across the US and Canada, has been notified that they will be facilitating the shipment of ViraTech UV-400 air purifiers to the Hockey Canada practice and training facility in Calgary.
The WinSport Canada facility operates under the scope of Hockey Canada, the national body regulating the sport across Canada. Located in Calgary's Canada Olympic Park, the 500,000-square-foot structure currently includes three North American-size ice rinks designed for hockey, sledge hockey as well as figure skaters. The facility has already been dubbed a calling card for Calgary in continuing to attract world-class athletes to the city.
With this shipment, scheduled for delivery upon completion of the facility, UV Flu will become an official supplier to Hockey Canada, and will continue to build brand awareness within the sport by directly introducing the product to the athletes who will benefit the most by its use. Hockey Canada will be an excellent addition to the growing list of teams and facilities utilizing the product including the Boston Bruins, Pittsburgh Penguins, and several notable college organizations.
"We believe we have not even scratched the surface for the potential demand of this product in the professional and college athletic marketplace," commented Charles Gulteri, President of NESSI. "Hockey and basketball are major sports where every player is critical to the team and the constant travel and changing weather conditions during cold and flu season create fertile conditions for the spread of illness. The UV-400 will prevent the spread of many of these airborne illnesses for an incredibly low price and we believe teams cannot afford to be without them in their team areas. We plan on talking with the NHL, as well as college teams, to further educate them on the importance of this product," said Mr. Gulteri.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the UnitedStates Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
CENTERVILLE, MA � February 1, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company's athletic distributor, New England Sports Sales ("NESSI"), a national distributor of hockey and related athletic equipment to college and professional hockey teams across the US and Canada, has been notified that they will be facilitating the shipment of ViraTech UV-400 air purifiers to the Hockey Canada practice and training facility in Calgary.
The WinSport Canada facility operates under the scope of Hockey Canada, the national body regulating the sport across Canada. Located in Calgary's Canada Olympic Park, the 500,000-square-foot structure currently includes three North American-size ice rinks designed for hockey, sledge hockey as well as figure skaters. The facility has already been dubbed a calling card for Calgary in continuing to attract world-class athletes to the city.
With this shipment, scheduled for delivery upon completion of the facility, UV Flu will become an official supplier to Hockey Canada, and will continue to build brand awareness within the sport by directly introducing the product to the athletes who will benefit the most by its use. Hockey Canada will be an excellent addition to the growing list of teams and facilities utilizing the product including the Boston Bruins, Pittsburgh Penguins, and several notable college organizations.
"We believe we have not even scratched the surface for the potential demand of this product in the professional and college athletic marketplace," commented Charles Gulteri, President of NESSI. "Hockey and basketball are major sports where every player is critical to the team and the constant travel and changing weather conditions during cold and flu season create fertile conditions for the spread of illness. The UV-400 will prevent the spread of many of these airborne illnesses for an incredibly low price and we believe teams cannot afford to be without them in their team areas. We plan on talking with the NHL, as well as college teams, to further educate them on the importance of this product," said Mr. Gulteri.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Consumer/ Retail Stocks; A New Audio Interview with Joseph Noel, CEO of YesDTC, is now at SmallCapVoice.com
AUSTIN, Texas - February 1, 2011 (Investorideas.com newswire) � SmallCapVoice.com, Inc. announced today that a new audio interview with YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, is now available. The interview can be heard at http://smallcapvoice.com/blog/1-31-11-audio-interview-with-yesdtc-holdings-inc-otcbb-yesd.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
YesDTC's growing product portfolio currently includes the NutriFusion line of easy-to-consume capsule and chewable nutraceutical supplement products; WordSmart, the knowledge and vocabulary building program sponsored by Alex Trebek of Jeopardy!; PureSleep Asia, the U.S. FDA-cleared anti-snoring dental device for the treatment of snoring; SimplyMusic(TM), the playing-based music education system; and MediPendant(TM), the only speak and listen through the pendant medical alarm system. The Company's infomercials for SimplyMusic, MediPendant, and WordSmart can be seen at the following links, respectively, www.trysimplymusic.com, www.medipendant.com, and http://www.vimeo.com/16363930. More information on NutriFusion can be seen at www.nutrifusion.com.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategicpartnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee five thousand and thirty thousand in shares
About Investorideas.com
- Investor Ideas the can change the world
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
AUSTIN, Texas - February 1, 2011 (Investorideas.com newswire) � SmallCapVoice.com, Inc. announced today that a new audio interview with YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, is now available. The interview can be heard at http://smallcapvoice.com/blog/1-31-11-audio-interview-with-yesdtc-holdings-inc-otcbb-yesd.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
YesDTC's growing product portfolio currently includes the NutriFusion line of easy-to-consume capsule and chewable nutraceutical supplement products; WordSmart, the knowledge and vocabulary building program sponsored by Alex Trebek of Jeopardy!; PureSleep Asia, the U.S. FDA-cleared anti-snoring dental device for the treatment of snoring; SimplyMusic(TM), the playing-based music education system; and MediPendant(TM), the only speak and listen through the pendant medical alarm system. The Company's infomercials for SimplyMusic, MediPendant, and WordSmart can be seen at the following links, respectively, www.trysimplymusic.com, www.medipendant.com, and http://www.vimeo.com/16363930. More information on NutriFusion can be seen at www.nutrifusion.com.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee five thousand and thirty thousand in shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.http://www.investorideas.com/Resources/Newsletter.asp
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Subscribe to:
Posts (Atom)